×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

ID: MRFR/Pharma/36951-HCR
100 Pages
Rahul Gotadki
October 2025

アンジオテンシン II 受容体拮抗薬の非ペプチド薬市場調査レポート 投与経路別(経口、静脈内、皮下)、治療領域別(高血圧、心不全、慢性腎臓病)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)、製剤タイプ別(錠剤、注射剤、液剤)および地域別(北部)アメリカ、ヨーロッパ、南アメリカ、アジア太平洋、中東、アフリカ) - 2034 年までの予測

共有
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
 Infographic
Purchase Options

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market 概要

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market 市場の主要企業には以下が含まれます

レポートの範囲

コメントを残す

FAQs

What is the projected market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2035?

The projected market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2035 is 6.52 USD Billion.

What was the market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2024?

The market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2024 was 4.275 USD Billion.

What is the expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market from 2025 to 2035?

The expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market during the forecast period 2025 - 2035 is 3.91%.

Which therapeutic area is projected to have the highest market value in 2035?

Chronic Kidney Disease is projected to have the highest market value in 2035, with an expected valuation of 2.4 USD Billion.

What are the leading companies in the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market?

Key players in the market include Novartis, Boehringer Ingelheim, AstraZeneca, Sanofi, Pfizer, Eli Lilly, Merck & Co., and Teva Pharmaceutical Industries.

How does the market for oral formulations compare to intravenous formulations in 2035?

In 2035, the market for oral formulations is expected to reach 3.8 USD Billion, while intravenous formulations are projected to reach 1.5 USD Billion.

What distribution channel is anticipated to generate the highest revenue by 2035?

Hospital Pharmacies are anticipated to generate the highest revenue by 2035, with a projected valuation of 2.3 USD Billion.

What is the expected market value for liquid formulations in 2035?

The expected market value for liquid formulations in 2035 is 1.12 USD Billion.

How does the market for heart failure treatments compare to hypertension treatments in 2035?

In 2035, the market for heart failure treatments is projected to reach 1.8 USD Billion, compared to 2.3 USD Billion for hypertension treatments.

What is the projected market value for online pharmacies in 2035?

The projected market value for online pharmacies in 2035 is 2.12 USD Billion.

無料サンプルをダウンロード

このレポートの無料サンプルを受け取るには、以下のフォームにご記入ください

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions